GenoDeep

GenoDeep is a pioneering AI startup revolutionizing cancer screening with its innovative deep learning algorithms. Using just an ordinary blood sample, GenoDeep can detect malignancy in eight types of cancers, including Ovary, Liver, Stomach, Pancreas, Esophagus, Colorectum, Lung, and Breast, at early stages. By analyzing altered cfDNAs and protein biomarkers from blood through its proprietary technology, GenoDeep aims to provide accurate and localized detection, significantly improving prognosis and treatment outcomes. Founded in 2018, GenoDeep operates at the intersection of Biotechnology, Health Care, and Machine Learning. The company's groundbreaking approach has garnered attention from venture capital firms and investors, positioning it as a game-changer in the realm of cancer diagnostics. As of now, specific details about its last investment and investors have not been publicly disclosed. In summary, GenoDeep's mission to transform cancer screening using AI-driven technology holds immense promise in reshaping the future of healthcare. As the company continues to advance its groundbreaking solution, it remains an intriguing prospect for investors seeking impactful opportunities within the rapidly evolving biotech and AI sectors.